Ascendis Pharma A/S Ascendis Pharma A/S

Ascendis Pharma A/S

ASND

Rangering i aksjer #1497
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Aksjekurs
$234.15
Markedsverdi
$14.61B
Endring (1 dag)
1.82%
Endring (1 år)
14.10%
Land
DK
Handel Ascendis Pharma A/S (ASND)

Kategori

Healthcare
Antall utestående aksjer for Ascendis Pharma A/S (ASND)
Antall utestående aksjer per June 2026: 64.34M
Ifølge Ascendis Pharma A/S sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 64.34M. Ved slutten av December 2024 hadde selskapet 57.89M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Ascendis Pharma A/S (ASND) fra 2012 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
2026 (TTM) 64.34M 6.17%
2025 60.61M 4.69%
2024 57.89M 2.85%
2023 56.29M 0.38%
2022 56.07M 2.37%
2021 54.77M 8.21%
2020 50.62M 8.84%
2019 46.51M 13.20%
2018 41.09M 22.18%
2017 33.63M 26.58%
2016 26.56M 12.16%
2015 23.68M 39.85%
2014 16.94M 56.78%
2013 10.80M 0.00%
2012 10.80M 0.00%
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 294.59%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 515.43%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 644.29%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -3.36%
NL